Skip to content
JCP
PCC
Insights
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
Insights
About
Authors & Reviewers
Sign In
Subscribe
Sign in
Subscribe
Clinical Topics
View All
Addiction
ADHD
Alzheimer’s Disease
Anxiety
Bipolar Disorder
Depression
Movement Disorders
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Schizophrenia/Schizoaffective Disorders
Sleep
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Evolving Psychedelic Paradigm
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
JCP Podcast
Rounds in the General Hospital
View All
Anzalee Khan, PhD
JCP
Original Research
MIN-101 and Cognition in Schizophrenia Patients
May 15, 2018
The currently available dopamine-blocking antipsychotics haven' t been of much help with cognitive deficits in schizophrenia. This post hoc analysis of an RCT examines whether MIN-101, which combines sigma-2...
Michael Davidson
,
Richard S. E. Keefe
,
Philip D. Harvey
, et al
JCP
Original Research
Effects of Olanzapine and Risperidone on Glucose Metabolism and Insulin Sensitivity in Chronic Schizophrenic Patients With Long-Term Antipsychotic Treatment: A Randomized 5-Month Study
October 6, 2009
Jean-Pierre Lindenmayer
,
John M. Davis
,
Robert C. Smith
, et al
JCP
Original Research
Outcome Evaluation of a Structured Educational Wellness Program in Patients With Severe Mental Illness
September 22, 2009
Jean-Pierre Lindenmayer
,
Saurabh Kaushik
,
Anzalee Khan
, et al
JCP
Original Research
A Randomized Controlled Trial of Olanzapine Versus Haloperidol in the Treatment of Primary Negative Symptoms and Neurocognitive Deficits in Schizophrenia
March 15, 2007
Jean-Pierre Lindenmayer
,
Adel Iskander
,
Anzalee Khan
, et al
